Published in Neuroimaging Clin N Am on November 01, 2005
Disturbed cingulate glutamate metabolism in adults with high-functioning autism spectrum disorder: evidence in support of the excitatory/inhibitory imbalance hypothesis. Mol Psychiatry (2014) 0.93
Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology (2013) 0.92
In vivo high-resolution localized (1) H MR spectroscopy in the awake rat brain at 7 T. Magn Reson Med (2012) 0.87
Anteroposterior hippocampal metabolic heterogeneity: three-dimensional multivoxel proton 1H MR spectroscopic imaging--initial findings. Radiology (2008) 0.82
Advances in high-field magnetic resonance spectroscopy in Alzheimer's disease. Curr Alzheimer Res (2014) 0.82
Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA (2011) 6.92
Exercise and pharmacotherapy in the treatment of major depressive disorder. Psychosom Med (2007) 4.49
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol (2012) 3.66
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol (2007) 3.22
Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. J Am Coll Cardiol (2012) 3.19
Treatment course with antidepressant therapy in late-life depression. Am J Psychiatry (2012) 2.94
Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol (2011) 2.81
Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One (2011) 2.30
Accuracy and precision of quantitative assessment of cartilage morphology by magnetic resonance imaging at 3.0T. Arthritis Rheum (2005) 2.15
Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy (2003) 1.93
Cognitive function in late life depression: relationships to depression severity, cerebrovascular risk factors and processing speed. Biol Psychiatry (2006) 1.92
Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology (2003) 1.87
Cortical deactivation in mild cognitive impairment: high-field-strength functional MR imaging. Radiology (2007) 1.77
Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology (2012) 1.74
Support for the vascular depression hypothesis in late-life depression: results of a 2-site, prospective, antidepressant treatment trial. Arch Gen Psychiatry (2010) 1.72
Combination drug therapy for Alzheimer's disease: what is evidence-based, and what is not? Geriatrics (2005) 1.52
Efficacy, safety, and tolerability of sertraline in patients with late-life depression and comorbid medical illness. J Am Geriatr Soc (2004) 1.49
Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging (2012) 1.43
Yoga on our minds: a systematic review of yoga for neuropsychiatric disorders. Front Psychiatry (2013) 1.40
Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry (2003) 1.40
Mild cognitive impairment: evaluation with 4-T functional MR imaging. Radiology (2006) 1.37
Pharmacovigilance in the 21st century: new systematic tools for an old problem. Pharmacotherapy (2004) 1.33
Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's MedWatch surveillance system and published reports. Pharmacotherapy (2003) 1.32
Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord (2013) 1.28
Prognostic value of posteromedial cortex deactivation in mild cognitive impairment. PLoS One (2007) 1.28
Olanzapine-associated diabetes mellitus. Pharmacotherapy (2002) 1.24
Cerebrovascular risk factors, vascular disease, and neuropsychological outcomes in adults with major depression. Psychosom Med (2007) 1.22
Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy (2006) 1.20
Trabecular morphometry by fractal signature analysis is a novel marker of osteoarthritis progression. Arthritis Rheum (2009) 1.17
Current status of metals as therapeutic targets in Alzheimer's disease. J Am Geriatr Soc (2003) 1.14
Donepezil for the treatment of language deficits in adults with Down syndrome: a preliminary 24-week open trial. Am J Med Genet A (2003) 1.10
Marked increase in Alzheimer's disease identified in medicare claims records between 1991 and 1999. J Gerontol A Biol Sci Med Sci (2004) 1.09
Exercise and pharmacotherapy in patients with major depression: one-year follow-up of the SMILE study. Psychosom Med (2010) 1.09
Frontal white matter anisotropy and antidepressant remission in late-life depression. PLoS One (2008) 1.09
Predicting memory decline in normal elderly: genetics, MRI, and cognitive reserve. Neurobiol Aging (2006) 1.05
Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. J Clin Psychiatry (2008) 1.05
Extracellular pH and P-31 magnetic resonance spectroscopic variables are related to outcome in canine soft tissue sarcomas treated with thermoradiotherapy. Clin Cancer Res (2006) 1.05
Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012. BMJ (2013) 1.03
Metabolomic changes in autopsy-confirmed Alzheimer's disease. Alzheimers Dement (2010) 1.02
Does meditation enhance cognition and brain plasticity? Ann N Y Acad Sci (2009) 1.02
Elevation in plasma Abeta42 in geriatric depression: a pilot study. Neurochem Res (2006) 1.02
Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study--rationale, design, and methodological issues. Clin Trials (2007) 1.01
Focal and lateralized subcortical abnormalities in unipolar major depressive disorder: an automated multivoxel proton magnetic resonance spectroscopy study. Biol Psychiatry (2003) 1.00
Hyperthermia MRI temperature measurement: evaluation of measurement stabilisation strategies for extremity and breast tumours. Int J Hyperthermia (2009) 1.00
The largest human cognitive performance dataset reveals insights into the effects of lifestyle factors and aging. Front Hum Neurosci (2013) 0.99
Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis. Psychopharmacol Bull (2009) 0.98
Association between pathologic gambling and parkinsonian therapy as detected in the Food and Drug Administration Adverse Event database. Arch Neurol (2006) 0.98
Delivering happiness: translating positive psychology intervention research for treating major and minor depressive disorders. J Altern Complement Med (2011) 0.97
Screening for Early Alzheimer's Disease: Is There Still a Role for the Mini-Mental State Examination? Prim Care Companion J Clin Psychiatry (2005) 0.95
Cognitive deficits following coronary artery bypass grafting: prevalence, prognosis, and therapeutic strategies. CNS Spectr (2004) 0.95
Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proc Natl Acad Sci U S A (2012) 0.95
Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates. J Neuropathol Exp Neurol (2014) 0.94
Donepezil effects on language in children with Down syndrome: results of the first 22-week pilot clinical trial. Am J Med Genet A (2004) 0.92
Effect of bupropion extended release on negative emotion processing in major depressive disorder: a pilot functional magnetic resonance imaging study. J Clin Psychiatry (2007) 0.91
Intima-media thickness and age of first depressive episode. Biol Psychol (2008) 0.91
Accuracy of spatial normalization of the hippocampus: implications for fMRI research in memory disorders. Neuroimage (2006) 0.91
Exercise fails to improve neurocognition in depressed middle-aged and older adults. Med Sci Sports Exerc (2008) 0.91
Quantitative imaging of cartilage morphology at 3.0 Tesla in the presence of gadopentate dimeglumine (Gd-DTPA). Magn Reson Med (2007) 0.91
Complex biomarker discovery in neuroimaging data: Finding a needle in a haystack. Neuroimage Clin (2013) 0.91
Cognitive improvement following treatment in late-life depression: relationship to vascular risk and age of onset. Am J Geriatr Psychiatry (2012) 0.90
A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry (2004) 0.89
A systematic review of antidepressant placebo-controlled trials for geriatric depression: limitations of current data and directions for the future. Neuropsychopharmacology (2004) 0.89
Exercise therapy for depression in middle-aged and older adults: predictors of early dropout and treatment failure. Health Psychol (2002) 0.89
Safety and efficacy of rivastigmine in adolescents with Down syndrome: a preliminary 20-week, open-label study. J Child Adolesc Psychopharmacol (2006) 0.89
Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review. J Clin Psychiatry (2014) 0.89
Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy (2003) 0.88
Relation between pO2, 31P magnetic resonance spectroscopy parameters and treatment outcome in patients with high-grade soft tissue sarcomas treated with thermoradiotherapy. Int J Radiat Oncol Biol Phys (2005) 0.87
Statins and cognition: what can we learn from existing randomized trials? CNS Spectr (2005) 0.87
Hippocampal volume and the Mini-Mental State Examination in the diagnosis of amnestic mild cognitive impairment. AJR Am J Roentgenol (2007) 0.87
Modulation of a human memory circuit by subsyndromal depression in late life: a functional magnetic resonance imaging study. Am J Geriatr Psychiatry (2009) 0.86
Therapeutic implications of HPA axis abnormalities in Alzheimer's disease: review and update. Psychopharmacol Bull (2003) 0.86
Coenzyme Q10: a review of its promise as a neuroprotectant. CNS Spectr (2007) 0.85
Learning and recall in subjects at genetic risk for Alzheimer's disease. J Neuropsychiatry Clin Neurosci (2002) 0.83
The Q7R Saitohin gene polymorphism is not associated with Alzheimer disease. Neurosci Lett (2003) 0.83
Health perception, pain, and disability as correlates of anxiety and depression symptoms in primary care patients. J Am Board Fam Pract (2002) 0.82
Prevalence of Alzheimer's pathologic endophenotypes in asymptomatic and mildly impaired first-degree relatives. PLoS One (2013) 0.82
Mifepristone (RU 486) for Alzheimer's disease. Neurology (2002) 0.82
Imaging genetics of brain longevity and mental wellness: the next frontier? Radiology (2008) 0.82
Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer's disease from normal cognitive aging. Acta Neuropathol Commun (2013) 0.81
Increasing memory load modulates regional brain activity in older adults as measured by fMRI. J Neuropsychiatry Clin Neurosci (2005) 0.81
Treatment of social anxiety disorder with citalopram. Prog Neuropsychopharmacol Biol Psychiatry (2002) 0.81
Review of the use of mirtazapine in the treatment of depression. Expert Opin Pharmacother (2011) 0.81
Anticholinergic drugs and elderly people: a no brainer? Lancet Neurol (2006) 0.81
Mapping the effects of ApoE4, age and cognitive status on 18F-florbetapir PET measured regional cortical patterns of beta-amyloid density and growth. Neuroimage (2013) 0.81
Functional MRI in the early diagnosis of Alzheimer's disease: is it time to refocus? Expert Rev Neurother (2008) 0.81
Physiorack: an integrated MRI safe/conditional, gas delivery, respiratory gating, and subject monitoring solution for structural and functional assessments of pulmonary function. J Magn Reson Imaging (2013) 0.80
Mood disorders and chronic obstructive pulmonary disease: current research and future needs. Curr Psychiatry Rep (2002) 0.80
Can lifestyle modification improve neurocognition? Rationale and design of the ENLIGHTEN clinical trial. Contemp Clin Trials (2012) 0.80
What constitutes clinical evidence for neuroprotection in Alzheimer disease: support for the cholinesterase inhibitors? Alzheimer Dis Assoc Disord (2006) 0.79
The Alzheimer structural connectome: changes in cortical network topology with increased amyloid plaque burden. Radiology (2014) 0.79
Perfluoropropane gas as a magnetic resonance lung imaging contrast agent in humans. Chest (2013) 0.79
From weight loss to weight gain: appetite changes in major depressive disorder as a mirror into brain-environment interactions. Front Psychol (2013) 0.79
The ADNI Publication Policy: commensurate recognition of critical contributors who are not authors. Neuroimage (2011) 0.79
Prefrontal activation patterns in subjects at risk for Alzheimer disease. Am J Geriatr Psychiatry (2002) 0.78
Cerebrovascular risk factors and cerebral hyperintensities among middle-aged and older adults with major depression. Am J Geriatr Psychiatry (2010) 0.78
Parsing the genetic heterogeneity of chromosome 12q susceptibility genes for Alzheimer disease by family-based association analysis. Neurogenetics (2006) 0.78
From the bridges of Konigsberg to the fields of Alzheimer: connecting the dots. Neurology (2013) 0.77